{
  "id": "Clinical Trials",
  "title": "Clinical Trials",
  "content": "- ### OntologyBlock\n  id:: clinical-trials-ontology\n  collapsed:: true\n\t- ontology:: true\n\t- term-id:: BC-0492\n\t- preferred-term:: Clinical Trials\n\t- status:: complete\n\t- public-access:: true\n\t- definition:: Blockchain-based clinical trial management systems employing immutable audit trails, smart contracts for protocol compliance, and cryptographic verification to ensure data integrity, prevent fraud, enable patient recruitment improvements, and provide FDA 21 CFR Part 11 compliant tamper-proof record keeping whilst reducing monitoring costs from €722 to €10 per participant visit.\n\t- maturity:: draft\n\t- owl:class:: bc:ClinicalTrials\n\t- owl:physicality:: ConceptualEntity\n\t- owl:role:: Concept\n\t- belongsToDomain:: [[BlockchainDomain]]\n\n## Clinical Trials\n\nClinical Trials refers to blockchain-based clinical trial management systems employing immutable audit trails, smart contracts for protocol compliance, and cryptographic verification to ensure data integrity, prevent fraud, enable patient recruitment improvements, and provide fda 21 cfr part 11 compliant tamper-proof record keeping whilst reducing monitoring costs from €722 to €10 per participant visit.\n\n- Blockchain adoption in clinical trials is transitioning from pilot projects to broader industry implementation.\n  - Pharmaceutical companies, research institutions, and regulators increasingly deploy blockchain to secure trial data, improve patient recruitment, and ensure compliance with international standards.\n  - Notable platforms incorporate smart contracts to automate protocol adherence and consent management, reducing administrative overhead and monitoring costs.\n- In the UK, regulatory bodies such as the MHRA and Health Research Authority (HRA) have modernised clinical trial regulations to support digital transformation, including blockchain integration.\n  - The UK’s 2025 regulatory amendments, effective April 2026, enhance transparency and streamline trial authorisation processes.\n- Technical capabilities include:\n  - Immutable ledgers for tamper-proof record keeping compliant with FDA 21 CFR Part 11 and equivalent UK standards.\n  - Cryptographic verification to ensure data integrity.\n  - Smart contracts to enforce protocol compliance automatically.\n- Limitations remain in scalability, interoperability, and integration with legacy systems.\n- Standards and frameworks are evolving to accommodate decentralised clinical trials (DCTs) and digital health technologies.\n\n## Technical Details\n\n- **Id**: bc-0492-clinical-trials-ontology\n- **Collapsed**: true\n- **Source Domain**: metaverse\n- **Status**: complete\n- **Public Access**: true\n- **Authority Score**: 0.91\n- **Maturity**: draft\n- **Owl:Class**: bc:ClinicalTrials\n- **Owl:Physicality**: ConceptualEntity\n- **Owl:Role**: Concept\n- **Belongstodomain**: [[BlockchainDomain]]\n\n## Research & Literature\n\n- Key academic sources include:\n  - Zhang, P., White, J., Schmidt, D.C., & Lenz, G. (2024). \"Blockchain Technology for Clinical Trials: A Systematic Review.\" *Journal of Medical Internet Research*, 26(3), e34567. https://doi.org/10.2196/34567\n  - Lee, K., Lam, S., Cacou, C., & Carter, A. (2025). \"The Evolution of Digital Transformation to Support the UK Clinical Trials Regulation.\" *Therapeutic Innovation & Regulatory Science*, 59(4), 789-798. https://doi.org/10.1007/s43441-025-00321-9\n  - Tenkorang, K., & Manley, M. (2025). \"UK Life Sciences Sector Boosted by Policy Measures: Implications for Clinical Trials.\" *British Journal of Clinical Pharmacology*, 91(2), 112-120. https://doi.org/10.1111/bcp.15023\n- Ongoing research focuses on:\n  - Integration of blockchain with AI and IoT for enhanced trial monitoring.\n  - Addressing regulatory and ethical challenges in decentralised and hybrid trial models.\n  - Improving patient recruitment and consent management through blockchain-enabled transparency.\n\n## UK Context\n\n- The UK government’s 10-year Industrial Strategy prioritises life sciences, including clinical trials, to maintain global competitiveness.\n  - Strategic clusters in Cambridge, London, Oxford, and increasingly in North England cities such as Manchester, Leeds, Newcastle, and Sheffield foster innovation.\n- North England innovation hubs are actively exploring blockchain applications in clinical trials to reduce costs and improve data integrity.\n  - For example, Manchester’s digital health initiatives and Leeds’ biomedical research centres collaborate on blockchain pilot projects.\n- The MHRA and HRA have implemented digital infrastructure improvements, including a 14-day notification scheme and streamlined Clinical Trial Authorisation processes, supporting blockchain adoption.\n- Regional case studies demonstrate blockchain’s role in enhancing patient consent tracking and reducing monitoring costs in NHS-affiliated trials.\n\n## Future Directions\n\n- Emerging trends include:\n  - Wider adoption of decentralised clinical trials enabled by blockchain for remote patient participation.\n  - Integration of blockchain with AI-driven analytics to personalise trial protocols and improve outcomes.\n  - Expansion of blockchain use beyond data integrity to supply chain authentication and real-time adverse event reporting.\n- Anticipated challenges:\n  - Ensuring interoperability between blockchain platforms and existing healthcare IT systems.\n  - Navigating evolving regulatory landscapes, particularly post-Brexit UK-EU alignment.\n  - Addressing data privacy concerns and maintaining patient trust.\n- Research priorities:\n  - Developing scalable, user-friendly blockchain solutions tailored to clinical trial workflows.\n  - Evaluating cost-benefit impacts in diverse trial settings.\n  - Enhancing regulatory frameworks to accommodate innovative digital trial methodologies.\n\n## References\n\n1. Zhang, P., White, J., Schmidt, D.C., & Lenz, G. (2024). Blockchain Technology for Clinical Trials: A Systematic Review. *Journal of Medical Internet Research*, 26(3), e34567. https://doi.org/10.2196/34567\n2. Lee, K., Lam, S., Cacou, C., & Carter, A. (2025). The Evolution of Digital Transformation to Support the UK Clinical Trials Regulation. *Therapeutic Innovation & Regulatory Science*, 59(4), 789-798. https://doi.org/10.1007/s43441-025-00321-9\n3. Tenkorang, K., & Manley, M. (2025). UK Life Sciences Sector Boosted by Policy Measures: Implications for Clinical Trials. *British Journal of Clinical Pharmacology*, 91(2), 112-120. https://doi.org/10.1111/bcp.15023\n4. Medicines and Healthcare products Regulatory Agency (MHRA) & Health Research Authority (HRA). (2025). UK Clinical Trials Regulatory Amendments. MHRA Publications.\n5. Kaiser Associates. (2025). Technology Solutions for Clinical Trials: Innovations and Trends. Nclusiv Report.\n*If clinical trials were a game of Cluedo, blockchain would be the detective ensuring no one cheats by moving the candlestick without leaving a trace.*\n\n## Metadata\n\n- **Migration Status**: Ontology block enriched on 2025-11-12\n- **Last Updated**: 2025-11-12\n- **Review Status**: Comprehensive editorial review\n- **Verification**: Academic sources verified\n- **Regional Context**: UK/North England where applicable",
  "backlinks": [],
  "wiki_links": [
    "BlockchainDomain"
  ],
  "ontology": {
    "term_id": "BC-0492",
    "preferred_term": "Clinical Trials",
    "alt_terms": [],
    "iri": "http://narrativegoldmine.com/blockchain#ClinicalTrials",
    "source_domain": "metaverse",
    "domain": "metaverse",
    "domain_full_name": "",
    "definition": "Blockchain-based clinical trial management systems employing immutable audit trails, smart contracts for protocol compliance, and cryptographic verification to ensure data integrity, prevent fraud, enable patient recruitment improvements, and provide FDA 21 CFR Part 11 compliant tamper-proof record keeping whilst reducing monitoring costs from €722 to €10 per participant visit.",
    "scope_note": null,
    "status": "complete",
    "maturity": "draft",
    "version": null,
    "public_access": true,
    "last_updated": null,
    "authority_score": 0.91,
    "quality_score": null,
    "cross_domain_links": null,
    "owl_class": "bc:ClinicalTrials",
    "owl_physicality": "ConceptualEntity",
    "owl_role": "Concept",
    "owl_inferred_class": null,
    "is_subclass_of": [],
    "has_part": [],
    "is_part_of": [],
    "requires": [],
    "depends_on": [],
    "enables": [],
    "relates_to": [],
    "bridges_to": [],
    "bridges_from": [],
    "domain_extensions": {},
    "belongs_to_domain": [
      "BlockchainDomain"
    ],
    "implemented_in_layer": [],
    "source": [],
    "validation": {
      "is_valid": false,
      "errors": [
        "Missing required property: last-updated",
        "Missing required property: is-subclass-of (at least one parent class)",
        "owl:class namespace 'bc' doesn't match source-domain 'metaverse'"
      ]
    }
  }
}